SMTL ID : 4v0g.2 (1 other biounit)

JAK3 in complex with a covalent EGFR inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.00 Å

Oligo State

monomer

Ligands

1 x G9B: N-[3-(2-{3-AMINO-6-[1-(1-METHYLPIPERIDIN-4-YL)-1H-PYRAZOL-4-YL]PYRAZIN-2-YL}-1H-BENZIMIDAZOL-1-YL)PHENYL]PROPANAMIDE(Covalent)

G9B.1: 17 residues within 4Å: Chain A: L.13, G.14, V.21, A.38, V.69, M.87, E.88, Y.89, L.90, P.91, G.93, C.94, R.96, D.97, R.138, L.141, D.152 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:V.21, A:V.21, A:D.152 Hydrogen bonds: A:E.88, A:L.90

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hennessy, E.J. et al., Utilisation of Structure Based Design to Identify Novel, Irreversible Inhibitors of the Epidermal Growth Factor Receptor (Egfr) Harboring the Gatekeeper T790M Mutation. To be Published

Release Date

2016-01-13

Peptides

TYROSINE-PROTEIN KINASE JAK3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

TYROSINE-PROTEIN KINASE JAK3